Muslimani Alaa A, Spiro Timothy P, Chaudhry Asif A, Taylor Harris C, Jaiyesimi Ishmael, Daw Hamed A
William Beaumont Hospital Rose Cancer Center, Royal Oak, MI 48073, USA.
Clin Adv Hematol Oncol. 2009 Dec;7(12):827-32.
Monoclonal gammopathy of undetermined significance (MGUS) is defined by the presence of a serum M-protein at a concentration of 3 g/dL or less, with less than 10% plasma cells in the bone marrow, and the absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the plasma cell proliferative process. The annual risk of MGUS progressing to a symptomatic plasma cell proliferation or other related malignancy is approximately 1%. The association between malignancy and venous thromboembolism (VTE) is well recognized. In this retrospective study of MGUS patients, VTE was seen in 8% (9/112) of patients, a rate that is 22.8-fold higher than that in the general population (P is less than .001). Although many studies have identified VTE as a marker for subsequent malignancy, we did not find a significant difference in the incidence of VTE as a function of the risk factor group.
意义未明的单克隆丙种球蛋白病（MGUS）的定义为：血清M蛋白浓度为3g/dL或更低，骨髓中浆细胞少于10%，且不存在与浆细胞增殖过程相关的溶骨性骨病变、贫血、高钙血症和肾功能不全。MGUS进展为有症状的浆细胞增殖或其他相关恶性肿瘤的年风险约为1%。恶性肿瘤与静脉血栓栓塞（VTE）之间的关联已得到充分认识。在这项对MGUS患者的回顾性研究中，8%（9/112）的患者出现了VTE，这一发生率比普通人群高22.8倍（P小于0.001）。尽管许多研究已将VTE确定为后续恶性肿瘤的标志物，但我们并未发现VTE发生率随危险因素分组存在显著差异。
